Celecoxib prevents pressure overload-induced cardiac hypertrophy and dysfunction by inhibiting inflammation, apoptosis and oxidative stress

Journal of Cellular and Molecular Medicine

Volumn 20, Issue 1, 2016, Pages 116-127

  Zhang, Chi ^a   Wang, Fan ^b   Zhang, Yingxia ^c   Kang, Yimin ^c   Wang, Haisheng ^c   Si, Mingming ^c   Su, Liping ^c   Xin, Xue ^c   Xue, Feng ^c   Hao, Fei ^c   Yu, Lechu ^a   Xu, Jinzhong ^d   Liu, Yanlong ^a   Xue, Mingming ^c  

^a WENZHOU MEDICAL UNIVERSITY   (China)

^b PEKING UNIVERSITY   (China)

^c INNER MONGOLIA MEDICAL UNIVERSITY   (China)

^d THE FIRST PEOPLE S HOSPITAL OF WENLING   (China)

Author keywords

Apoptosis; Cardiac hypertrophy; Celecoxib; Inflammation; Oxidative stress; Pressure overload

Indexed keywords

CELECOXIB; MAJOR HISTOCOMPATIBILITY ANTIGEN; CARDIOTONIC AGENT; CYCLOOXYGENASE 2 INHIBITOR;

ANIMAL EXPERIMENT; ANIMAL TISSUE; AORTA CONSTRICTION; APOPTOSIS; ARTICLE; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; GENE EXPRESSION; HEART EJECTION FRACTION; HEART FUNCTION; HEART HYPERTROPHY; HEART MUSCLE CELL; HEART MUSCLE FIBROSIS; HISTOPATHOLOGY; HYPERTENSION; INFLAMMATION; MALE; MORTALITY; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; REAL TIME POLYMERASE CHAIN REACTION; SURVIVAL; SYSTOLIC BLOOD PRESSURE; TRANSTHORACIC ECHOCARDIOGRAPHY; TUNEL ASSAY; WESTERN BLOTTING; ANIMAL; CARDIAC MUSCLE; CARDIAC MUSCLE CELL; CARDIOMEGALY; CELL SURVIVAL; COMPLICATION; DRUG EFFECTS; HEART VENTRICLE REMODELING; PATHOLOGY; PHYSIOLOGY; PRECLINICAL STUDY; WISTAR RAT;

ANIMALS; APOPTOSIS; CARDIOMEGALY; CARDIOTONIC AGENTS; CELECOXIB; CELL SURVIVAL; CYCLOOXYGENASE 2 INHIBITORS; DRUG EVALUATION, PRECLINICAL; HYPERTENSION; MALE; MYOCARDIUM; MYOCYTES, CARDIAC; OXIDATIVE STRESS; RATS, WISTAR; VENTRICULAR REMODELING;

EID: 84956589750     PISSN: 15821838     EISSN: None     Source Type: Journal    
DOI: 10.1111/jcmm.12709     Document Type: Article

References (62)

1. Nadruz W. Myocardial remodeling in hypertension. J Hum Hypertens. 2015; 29: 1-6.
2. Yamamoto S, Kita S, Iyoda T, et al. New molecular mechanisms for cardiovascular disease: cardiac hypertrophy and cell-volume regulation. J Pharmacol Sci. 2011; 116: 343-9.
3. Barry SP, Davidson SM, Townsend PA. Molecular regulation of cardiac hypertrophy. Int J Biochem Cell Biol. 2008; 40: 2023-39.
4. Lu FH, Fu SB, Leng X, et al. Role of the calcium-sensing receptor in cardiomyocyte apoptosis via the sarcoplasmic reticulum and mitochondrial death pathway in cardiac hypertrophy and heart failure. Cell Physiol Biochem. 2013; 31: 728-43.
5. Shenje LT, Andersen P, Halushka MK, et al. Mutations in Alstrom protein impair terminal differentiation of cardiomyocytes. Nat Commun. 2014; 5: 3416.
6. Lovric J, Mano M, Zentilin L, et al. Terminal differentiation of cardiac and skeletal myocytes induces permissivity to AAV transduction by relieving inhibition imposed by DNA damage response proteins. Mol Ther. 2012; 20: 2087-97.
7. Frohlich ED, Susic D. Pressure overload. Heart Fail Clin. 2012; 8: 21-32.
8. Adeghate E. Molecular and cellular basis of the aetiology and management of diabetic cardiomyopathy: a short review. Mol Cell Biochem. 2004; 261: 187-91.
9. van Empel VP, De Windt LJ. Myocyte hypertrophy and apoptosis: a balancing act. Cardiovasc Res. 2004; 63: 487-99.
10. Wollert KC, Drexler H. Regulation of cardiac remodeling by nitric oxide: focus on cardiac myocyte hypertrophy and apoptosis. Heart Fail Rev. 2002; 7: 317-25.
11. Honsho S, Nishikawa S, Amano K, et al. Pressure-mediated hypertrophy and mechanical stretch induces IL-1 release and subsequent IGF-1 generation to maintain compensative hypertrophy by affecting Akt and JNK pathways. Circ Res. 2009; 105: 1149-58.
12. Weber KT, Jalil JE, Janicki JS, et al. Myocardial collagen remodeling in pressure overload hypertrophy. A case for interstitial heart disease. Am J Hypertens. 1989; 2: 931-40.
13. Rossi MA. Pathologic fibrosis and connective tissue matrix in left ventricular hypertrophy due to chronic arterial hypertension in humans. J Hypertens. 1998; 16: 1031-41.
14. Maulik SK, Kumar S. Oxidative stress and cardiac hypertrophy: a review. Toxicol Mech Methods. 2012; 22: 359-66.
15. O'Connor JP, Lysz T. Celecoxib, NSAIDs and the skeleton. Drugs Today. 2008; 44: 693-709.
16. Sciulli MG, Capone ML, Tacconelli S, et al. The future of traditional nonsteroidal antiinflammatory drugs and cyclooxygenase-2 inhibitors in the treatment of inflammation and pain. Pharmacol Rep. 2005; 57: 66-85.
17. Kismet K, Akay MT, Abbasoglu O, et al. Celecoxib: a potent cyclooxygenase-2 inhibitor in cancer prevention. Cancer Detect Prev. 2004; 28: 127-42.
18. Koul A, Arora N. Celecoxib mitigates cigarette smoke induced oxidative stress in mice. Indian J Biochem Biophys. 2010; 47: 285-91.
19. Ozturk H, Gezici A, Ozturk H. The effect of celecoxib, a selective COX-2 inhibitor, on liver ischemia/reperfusion-induced oxidative stress in rats. Hepatol Res. 2006; 34: 76-83.
20. Jendrossek V. Targeting apoptosis pathways by Celecoxib in cancer. Cancer Lett. 2013; 332: 313-24.
21. Sobolewski C, Muller F, Cerella C, et al. Celecoxib prevents curcumin-induced apoptosis in a hematopoietic cancer cell model. Mol Carcinog. 2015; 54: 999-1013.
22. Fan X, Takahashi-Yanaga F, Morimoto S, et al. Celecoxib and 2, 5-dimethyl-celecoxib prevent cardiac remodeling inhibiting Akt-mediated signal transduction in an inherited dilated cardiomyopathy mouse model. J Pharmacol Exp Ther. 2011; 338: 2-11.
23. Hamdulay SS, Wang B, Birdsey GM, et al. Celecoxib activates PI-3K/Akt and mitochondrial redox signaling to enhance heme oxygenase-1-mediated anti-inflammatory activity in vascular endothelium. Free Radic Biol Med. 2010; 48: 1013-23.
24. Wang BH, Bertucci MC, Ma JY, et al. Celecoxib, but not rofecoxib or naproxen, attenuates cardiac hypertrophy and fibrosis induced in vitro by angiotensin and aldosterone. Clin Exp Pharmacol Physiol. 2010; 37: 912-8.
25. Marano G, Palazzesi S, Fadda A, et al. Attenuation of aortic banding-induced cardiac hypertrophy by propranolol is independent of beta-adrenoceptor blockade. J Hypertens. 2002; 20: 763-9.
26. Fan LW, Kaizaki A, Tien LT, et al. Celecoxib attenuates systemic lipopolysaccharide-induced brain inflammation and white matter injury in the neonatal rats. Neuroscience. 2013; 240: 27-38.
27. Ma Y, Gao S, Hu M. Quantitation of celecoxib and four of its metabolites in rat blood by UPLC-MS/MS clarifies their blood distribution patterns and provides more accurate pharmacokinetics profiles. J Chromatogr B Analyt Technol Biomed Life Sci. 2015; 1001: 202-11.
28. Tan Y, Li X, Prabhu SD, et al. Angiotensin II plays a critical role in alcohol-induced cardiac nitrative damage, cell death, remodeling, and cardiomyopathy in a protein kinase C/nicotinamide adenine dinucleotide phosphate oxidase-dependent manner. J Am Coll Cardiol. 2012; 59: 1477-86.
29. Basu R, Oudit GY, Wang X, et al. Type 1 diabetic cardiomyopathy in the Akita (Ins2WT/C96Y) mouse model is characterized by lipotoxicity and diastolic dysfunction with preserved systolic function. Am J Physiol Heart Circ Physiol. 2009; 297: H2096-108.
30. Shao M, Lu X, Cong W, et al. Multiple low-dose radiation prevents type 2 diabetes-induced renal damage through attenuation of dyslipidemia and insulin resistance and subsequent renal inflammation and oxidative stress. PLoS ONE. 2014; 9: e92574.
31. Zhou G, Li X, Hein DW, et al. Metallothionein suppresses angiotensin II-induced nicotinamide adenine dinucleotide phosphate oxidase activation, nitrosative stress, apoptosis, and pathological remodeling in the diabetic heart. J Am Coll Cardiol. 2008; 52: 655-66.
32. Cai L, Wang Y, Zhou G, et al. Attenuation by metallothionein of early cardiac cell death via suppression of mitochondrial oxidative stress results in a prevention of diabetic cardiomyopathy. J Am Coll Cardiol. 2006; 48: 1688-97.
33. Li Y, Ha T, Gao X, et al. NF-kappaB activation is required for the development of cardiac hypertrophy in vivo. Am J Physiol Heart Circ Physiol. 2004; 287: H1712-20.
34. Frey N, Olson EN. Cardiac hypertrophy: the good, the bad, and the ugly. Annu Rev Physiol. 2003; 65: 45-79.
35. Gupta PK, DiPette DJ, Supowit SC. Protective effect of resveratrol against pressure overload-induced heart failure. Food Sci Nutr. 2014; 2: 218-29.
36. Juric D, Wojciechowski P, Das DK, et al. Prevention of concentric hypertrophy and diastolic impairment in aortic-banded rats treated with resveratrol. Am J Physiol Heart Circ Physiol. 2007; 292: H2138-43.
37. Wojciechowski P, Juric D, Louis XL, et al. Resveratrol arrests and regresses the development of pressure overload- but not volume overload-induced cardiac hypertrophy in rats. J Nutr. 2010; 140: 962-8.
38. Yu S, Li G. MicroRNA expression and function in cardiac ischemic injury. J Cardiovasc Transl Res. 2010; 3: 241-5.
39. Bursac N. Cardiac fibroblasts in pressure overload hypertrophy: the enemy within? J Clin Invest. 2014; 124: 2850-3.
40. Pereira RO, Wende AR, Crum A, et al. Maintaining PGC-1alpha expression following pressure overload-induced cardiac hypertrophy preserves angiogenesis but not contractile or mitochondrial function. FASEB J. 2014; 28: 3691-702.
41. Moens AL, Ketner EA, Takimoto E, et al. Bi-modal dose-dependent cardiac response to tetrahydrobiopterin in pressure-overload induced hypertrophy and heart failure. J Mol Cell Cardiol. 2011; 51: 564-9.
42. Corno AF, Cai X, Jones CB, et al. Congestive heart failure: experimental model. Front Pediatr. 2013; 1: 33.
43. Jalili T, Carlstrom J, Kim S, et al. Quercetin-supplemented diets lower blood pressure and attenuate cardiac hypertrophy in rats with aortic constriction. J Cardiovasc Pharmacol. 2006; 47: 531-41.
44. Kuipers I, Li J, Vreeswijk-Baudoin I, et al. Activation of liver X receptors with T0901317 attenuates cardiac hypertrophy in vivo. Eur J Heart Fail. 2010; 12: 1042-50.
45. Dai WJ, Dong Q, Chen MS, et al. Alterations in cardiac structure and function in a modified rat model of myocardial hypertrophy. J Huazhong Univ Sci Technolog Med Sci. 2014; 34: 626-33.
46. Tindall E. Celecoxib for the treatment of pain and inflammation: the preclinical and clinical results. J Am Osteopath Assoc. 1999; 99: S13-7.
47. Antoniou K, Malamas M, Drosos AA. Clinical pharmacology of celecoxib, a COX-2 selective inhibitor. Expert Opin Pharmacother. 2007; 8: 1719-32.
48. Tive L. Celecoxib clinical profile. Rheumatology. 2000; 39: 21-8; discussion 57-9.
49. Setia S, Nehru B, Sanyal SN. The PI3K/Akt pathway in colitis associated colon cancer and its chemoprevention with celecoxib, a Cox-2 selective inhibitor. Biomed Pharmacother. 2014; 68: 721-7.
50. Cao Y, Qu J, Li C, et al. Celecoxib sensitizes gastric cancer to rapamycin via inhibition of the Cbl-b-regulated PI3K/Akt pathway. Tumour Biol. 2015; 36: 5607-15.
51. Wang JS, Ho FM, Kang HC, et al. Celecoxib induces heme oxygenase-1 expression in macrophages and vascular smooth muscle cells via ROS-dependent signaling pathway. Naunyn Schmiedebergs Arch Pharmacol. 2011; 383: 159-68.
52. Brophy JM. Celecoxib and cardiovascular risks. Expert Opin Drug Saf. 2005; 4: 1005-15.
53. Suarez J, Gloss B, Belke DD, et al. Doxycycline inducible expression of SERCA2a improves calcium handling and reverts cardiac dysfunction in pressure overload-induced cardiac hypertrophy. Am J Physiol Heart Circ Physiol. 2004; 287: H2164-72.
54. Agabiti-Rosei E, Muiesan ML. Cardiac hypertrophy and hypertension. Curr Opin Nephrol Hypertens. 1998; 7: 211-6.
55. Cai L, Kang YJ. Cell death and diabetic cardiomyopathy. Cardiovasc Toxicol. 2003; 3: 219-28.
56. Boudina S, Abel ED. Diabetic cardiomyopathy revisited. Circulation. 2007; 115: 3213-23.
57. Boudina S, Abel ED. Diabetic cardiomyopathy, causes and effects. Rev Endocr Metab Disord. 2010; 11: 31-9.
58. Cai L, Wang J, Li Y, et al. Inhibition of superoxide generation and associated nitrosative damage is involved in metallothionein prevention of diabetic cardiomyopathy. Diabetes. 2005; 54: 1829-37.
59. Higuchi Y, Otsu K, Nishida K, et al. Involvement of reactive oxygen species-mediated NF-kappa B activation in TNF-alpha-induced cardiomyocyte hypertrophy. J Mol Cell Cardiol. 2002; 34: 233-40.
60. Smith RM, McCarthy J, Sack MN. TNF alpha is required for hypoxia-mediated right ventricular hypertrophy. Mol Cell Biochem. 2001; 219: 139-43.
61. Singh R, Singh AP, Singh M, et al. Impact of obesity on hypertension-induced cardiac remodeling: role of oxidative stress and its modulation by gemfibrozil treatment in rats. Free Radic Biol Med. 2011; 50: 363-70.
62. El-Sayed RM, Moustafa YM, El-Azab MF. Evening primrose oil and celecoxib inhibited pathological angiogenesis, inflammation, and oxidative stress in adjuvant-induced arthritis: novel role of angiopoietin-1. Inflammopharmacology. 2014; 22: 305-17.